We claim:

1. A combination comprising pure 5-HT_6 receptor antagonist and acetylcholinesterase inhibitor;
wherein:
the pure 5-HT_6 receptor antagonist is selected from,
1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
1-[(4-Fluorophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole; and
1-[(4-Isopropylphenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
or a pharmaceutically acceptable salt thereof.

2. The combination as claimed in claim 1, wherein the pure 5-HT_6 receptor antagonist is, 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof.

3. The combination as claimed in claim 1 or claim 2, wherein the pharmaceutically acceptable salt of the pure 5-HT_6 receptor antagonist is,
1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate;
1-[(4-Fluorophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dihydrochloride; and
1-[(4-Isopropylphenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dihydrochloride.

4. The combination as claimed in any one of the claim 1 to 3, wherein the acetylcholinesterase inhibitor is donepezil, galantamine and rivastigmine or a pharmaceutically acceptable salt thereof.

5. The combination as claimed in any one of the claim 1 to 4, wherein the acetylcholinesterase inhibitor is donepezil and rivastigmine or a pharmaceutically acceptable salt thereof.

6. The combination as claimed in any one of the claim 1 to 5, wherein the acetylcholinesterase inhibitor, donepezil or a pharmaceutically acceptable salt thereof is donepezil hydrochloride.

7. The combination as claimed in any one of the claim 1 to 6, for use in the treatment of cognitive disorders in a patient.

8. The use as claimed in claim 7, wherein the cognitive disorder is selected from Alzheimer's disease, schizophrenia, Parkinson's disease, lewy body dementia, vascular dementia and frontotemporal dementia.

9. A method of treatment of cognitive disorder comprising administering to a patient in need thereof, a therapeutically effective amount of the combination as claimed in any one of the claim 1 to 6.

10. The method of treatment as claimed in 9, wherein the cognitive disorder is selected from Alzheimer's disease, schizophrenia, Parkinson's disease, lewy body dementia, vascular dementia and frontotemporal dementia.

11. A compound, 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl) methyl]-1H-indole or a pharmaceutically acceptable salt thereof for use in combination with acetylcholinesterase inhibitor for the treatment of Alzheimer's disease in a patient.

12. The compound for use according to claim 11, as an adjunct treatment in a patient on stable treatment with an acetylcholinesterase inhibitor.

13. The compound for use as claimed in any one of the claim 11 or claim 12, wherein the acetylcholinesterase inhibitor is selected from donepezil, galantamine and rivastigmine or a pharmaceutically acceptable salt thereof.

14. The compound for use as claimed in any one of the claim 11 to 13, wherein the acetylcholinesterase inhibitor is donepezil and rivastigmine or a pharmaceutically acceptable salt thereof.

15. The compound for use as claimed in claim 11 or claim 12, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or

a pharmaceutically acceptable salt thereof is 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate.

16. A method of treating Alzheimer's disease in a patient comprising administering to said patient a therapeutically effective amount of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof and acetylcholinesterase inhibitor.

17. A method of treating Alzheimer's disease in a patient on stable treatment with acetylcholinesterase inhibitor comprising administering to said patient a therapeutically effective amount of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof.

18. The method as claimed in claim 16 or claim 17, wherein the pharmaceutically acceptable salt of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole is 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate.

19. The method as claimed in claim 16 or claim 17, wherein the acetylcholinesterase inhibitor is donepezil and rivastigmine or a pharmaceutically acceptable salt thereof.

20. The method of treating Alzheimer's disease as claimed in claim 16, wherein the patient is administered 1 mg to 200 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof per day.

21. The method of treating Alzheimer's disease as claimed in claim 16, wherein the patient is administered 1 mg to 10 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof per day.

22. The method of treating Alzheimer's disease as claimed in claim 16, wherein the patient is administered 25 mg to 125 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof per day.

23. The method of treating Alzheimer's disease as claimed in claim 16, wherein the patient is administered 150 mg to 200 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof per day.

24. The method of treating Alzheimer's disease as claimed in claim 16, wherein the patient is administered 25 mg to 75 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or pharmaceutically acceptable salt per day.

25. The method of treating Alzheimer's disease as claimed in claim 16, wherein the patient is administered 75 mg to 150 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof per day.

26. The method of treating Alzheimer's disease as claimed in claim 16, wherein the patient is administered 1 mg to 30 mg of donepezil or a pharmaceutically acceptable salt thereof per day.

27. The method of treating Alzheimer's disease as claimed in claim 16, wherein the patient is administered 5 mg to 25 mg of donepezil or a pharmaceutically acceptable salt thereof per day.

28. The method of treating Alzheimer's disease as claimed in claim 16, wherein the patient is administered 10 mg to 25 mg donepezil or a pharmaceutically acceptable salt thereof per day.

29. A pharmaceutical composition comprising the combination as claimed in any one of the claim 1 to 6, and pharmaceutically acceptable excipients or combination thereof.

30. The pharmaceutical composition as claimed in claim 29, for use in the treatment of cognitive disorders selected from Alzheimer's disease, schizophrenia, Parkinson's disease, lewy body dementia, vascular dementia and frontotemporal dementia.

31. The pharmaceutical composition as claimed in claim 29 or claim 30, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 1 mg to 300 mg.

32. The pharmaceutical composition as claimed in claim 29 or claim 30, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 35 mg to 200 mg.

33. The pharmaceutical composition as claimed in claim 29 or claim 30, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 200 mg to 300 mg.

34. The pharmaceutical composition as claimed in claim 29 or claim 30, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 75 mg or 150 mg.

35. The pharmaceutical composition as claimed in claim 29 or claim 30, wherein the donepezil or a pharmaceutically acceptable salt thereof is present in an amount of 2 mg to 30 mg.

36. The pharmaceutical composition as claimed in claim 29 or claim 30, wherein the donepezil or a pharmaceutically acceptable salt thereof is present in an amount of 5 mg to 25 mg.

37. The pharmaceutical composition as claimed in claim 29 or claim 30, wherein the donepezil or a pharmaceutically acceptable salt thereof is present in an amount of 5 mg.

38. The pharmaceutical composition as claimed in claim 29 or claim 30, wherein the donepezil or a pharmaceutically acceptable salt thereof is present in an amount of 10 mg.

39. The pharmaceutical composition as claimed in claim 29 or claim 30, wherein the donepezil or a pharmaceutically acceptable salt thereof is present in an amount of 23 mg.

40. The method of treating Alzheimer's disease as claimed in claim 16, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is administered to the patient by oral, nasal, local, dermal or parenteral routes.

41. The method of treating Alzheimer's disease as claimed in claim 16, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is administered to the patient one to three times per day, one to three times per week or one to three times per month.